Hyderabad-based Sai Life Sciences, one of India’s fastest growing contract development and manufacturing organizations (CDMOs), announced the inauguration of its new research and technology (R&T) center in Hyderabad, India. KT Rama Rao, minister for Industry and Commerce and IT, Government of Telangana formally inaugurated the facility in the presence of other dignitaries.
Speaking on occasion, Rao said, “I’m very happy that the esteemed leadership of Sai Life sciences has considered Telangana for setting up their new R&D center. Life Sciences is one of the key focus sectors for the Government of Telangana. Hyderabad serves more than 1000 global innovators in their vision to develop innovative and affordable medicines for the world. I sincerely congratulate the entire team of Sai Life Sciences, not only for the new research and technology center but, also for their work towards the development and manufacturing of new life saving medicines.”
Built with an aspiration to achieve the best global benchmarks in lab infrastructure, the new R&T facility, according to the press release has several unique aspects such as intelligent and ergonomic lab design to enhance safety and productivity, advanced automation for seamless data capture during process development, lean and 5S approach to enhance productivity and collaborative workspaces for engendering innovation.
Making the announcement, Krishna Kanumuri, chief executive officer and managing director of Sai Life Sciences, said, “Our philosophy behind building this new facility was to go beyond what the norm is in India and to create what our global innovator partners expect in their inhouse capabilities.” He further added, “We are an example of what is possible in Hyderabad’s rich life sciences ecosystem. Today, as we build world class R&D capabilities and invest in nurturing talent with deep domain expertise, I can unhesitatingly say, Hyderabad is truly a city where pharma dreams are made.”
The new 83,000 sqft (7700 sqm) facility, according to the press release houses state-of-the-art research capabilities and advanced technology platforms, augmenting the company’s capabilities in providing scientific solutions to its pharma and biotech innovator customers globally. It has 24 chemistry labs with 250 fume hoods, analytical labs, a fully equipped technology suite, and a dedicated process safety lab.
Sai Life Sciences began a process of organizational transformation in 2019, reinventing itself as a new generation global CDMO. Through this initiative, named Sai Nxt, the company is investing over US$ 150 million (approximately Rs 1000 crore) to expand and upgrade its R&D and manufacturing facilities, induct top-notch global scientific and leadership talent, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.
Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines by 2025. It works with innovator pharma and biotech companies globally, accelerating the discovery, development, and manufacture of complex small molecules. Sai Life Sciences has served a diverse set of NCE development programs, consistently delivering value based on its quality and responsiveness. Today, it works with 7 of the top 10 large pharma companies and several small and mid-sized pharma and biotech companies. Sai Life Sciences is privately held and backed by global investors, TPG Capital, and HBM Healthcare Investments.
